For how we live.
A six-month randomised trial found liver-fat improvement tracked weight loss and lower ultra-processed food intake, not whether people were assigned a Mediterranean or low-carbohydrate pattern.
In ESSENCE, the first 800 patients with biopsy-confirmed fatty-liver disease were analysed at week 72. Steatohepatitis resolved in 62.9% on semaglutide versus 34.3% on placebo — an interim look at an ongoing trial.
A Lancet review triangulates the evidence linking adiposity to multisystem disease and finds robust trial support in a short list — while an expert panel argues the drugs must be lifelong.
Pooling 291 participants, researchers found time-restricted eating modestly lowered a liver enzyme and body mass index — but didn't significantly reduce liver fat itself or improve insulin resistance.
SYNCHRONIZE-MASLD reports 84.2% of survodutide patients hitting a 30% cut in liver fat at 48 weeks. The trial measured fat on MRI, not fibrosis on biopsy — which is where the harder question still sits.
Two 2026 reviews describe the same handover: as the virus recedes, obesity-driven fatty liver disease is moving into the space it occupied — in a population where roughly 40% of screened adults met obesity criteria.